Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report results for once-daily adavosertib. A 3 + 3 dose-escalation desi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-07, Vol.27 (14), p.3834-3844
Hauptverfasser:	Takebe, Naoko, Naqash, Abdul Rafeh, O'Sullivan Coyne, Geraldine, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B, Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J, Parchment, Ralph E, Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H, Chen, Alice P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biomarkers, Tumor - analysis Cell Cycle Proteins - antagonists & inhibitors Drug Administration Schedule Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Humans Male Middle Aged Neoplasms - chemistry Neoplasms - drug therapy Protein-Tyrosine Kinases - antagonists & inhibitors Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidinones - adverse effects Pyrimidinones - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!